CUV.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:10):

Stats
Šios dienos apimtis	45 805.00
Vidutinė apimtis	139 228
Rinkos kapitalizacija	744.54M
EPS	$0 ( 2024-02-21 )
Last Dividend	$0.0500 ( 2023-09-05 )
Next Dividend	$0 ( N/A )
P/E	26.07
ATR14	$0.0210 (0.14%)

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -0.36 (neutral)

Signal:(70.379) Neutral

Clinuvel Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Clinuvel Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.51
( weak )

0.24
( neutral )

0.00
( neutral )

0.08
( neutral )

0.21
( neutral )

-0.37
( neutral )

Clinuvel Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$78.32M
Bruto pelnas:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
Pajamos:	$78.32M
Bruto pelnas:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
Pajamos:	$65.72M
Bruto pelnas:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
Pajamos:	$47.98M
Bruto pelnas:	$43.26M (90.16 %)
EPS:	$0.513

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0400 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.96 - Stable (39.22%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0200	2018-09-21
Last Dividend	$0.0500	2023-09-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.185	--
Avg. Dividend % Per Year	0.00%	--
Score	3.16	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.96
Div. Directional Score	8.66	--

Next Divdend (Est)
(2024-07-01)

$0.0598 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.16

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
IPH.AX	Ex Dividend Knight	2023-08-22	Semi-Annually	0.00%
SIG.AX	Ex Dividend Knight	2023-09-25	Annually	0.00%
CGF.AX	Ex Dividend Junior	2023-08-28	Annually	0.00%
MIR.AX	Ex Dividend Knight	2023-07-28	Semi-Annually	0.00%
URF.AX	No Dividend Player	2023-06-29	Annually	0.00%
DDR.AX	Ex Dividend Knight	2023-08-16	Quarterly	0.00%
OCL.AX	Ex Dividend Knight	2023-09-08	Annually	0.00%
ACQ.AX	Ex Dividend Knight	2023-11-09	Semi-Annually	0.00%
GCI.AX	Ex Dividend Knight	2023-08-31	Monthly	0.00%
QBE.AX	Ex Dividend Knight	2023-08-17	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.90	1.000	7.59	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.334	1.500	1.656	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	1.046	1.500	6.36	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				6.96

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.